Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 3/20 | 0.46 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.46 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1488965 | 0.87 | ERCC1 (0.47) | ERCC1ERCC4L3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL19045455 | 0.85 | ERCC1 (0.46) | ERCC1ERCC4L3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL348979 | 0.83 | KEAP1 (0.50) | ERCC1ERCC4CYP2C9TP53HTR1A | |
| SCHEMBL29434734 | 0.83 | KEAP1 (0.50) | ERCC1ERCC4CYP2C9TP53HTR1A | |
| SCHEMBL6184686 | 0.83 | SIRT1 (0.46) | ERCC1ERCC4SIRT1MEN1ALDH1A1 | |
| SCHEMBL19030836 | 0.81 | ERCC1 (0.46) | ERCC1ERCC4L3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL29718886 | 0.81 | L3MBTL1 (0.55) | ERCC1ERCC4L3MBTL1TP53MEN1 | |
| SCHEMBL260323 | 0.81 | L3MBTL1 (0.55) | ERCC1ERCC4L3MBTL1TP53MEN1 | |
| SCHEMBL30148003 | 0.81 | MAPK8 (0.52) | ICMT | |
| SCHEMBL1115269 | 0.81 | MAPK8 (0.52) | ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2004-07-29 | — | — | US | claimed |
| EP-1294688-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2003-03-26 | — | — | EP | claimed |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2002-05-02 | — | — | US | claimed |
| WO-2001094312-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-12-13 | — | — | WO | claimed |
| EP-3436437-B1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10952435-B2 | Pyridine-2-carboxamides as nematocides | SYNGENTA PARTICIPATIONS AG (CH) | 2021-03-23 | — | — | US | disclosed |
| US-10689340-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190112266-A1 | Substituted indoline derivatives as dengue viral replication inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-18 | — | — | US | disclosed |
| EP-3022181-B1 | PYRIDINE-2-CARBOXAMIDES AS NEMATOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-03-07 | — | — | EP | disclosed |
| WO-2017167951-A1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20160165887-A1 | PYRIDINE-2-CARBOXAMIDES AS NEMATOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-16 | — | — | US | disclosed |
| EP-3022181-A1 | PYRIDINE-2-CARBOXAMIDES AS NEMATOCIDES | Syngenta Participations AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| EP-1836191-A1 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| US-7071332-B2 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| WO-2006067391-A1 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2004-07-29 | — | — | US | disclosed |
| US-6706709-B2 | TREATING, FOR EXAMPLE, PROLIFERATIVE DISORDERS INCLUDING CANCER | SUGEN, INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1294688-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2001094312-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112266-A1 | Substituted indoline derivatives as dengue viral replication inhibitors | IDO1, INMT, IRF3 | ICMT 15/4885ERCC1 3825/4885ERCC4 2644/4885 |
| US-10689340-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | IDO1, INMT, IRF3 | ICMT 15/4885ERCC1 3825/4885ERCC4 2644/4885 |
| US-20160165887-A1 | PYRIDINE-2-CARBOXAMIDES AS NEMATOCIDES | TUBA3C, CYCS, ACHE | ICMT 2471/4885ERCC1 4293/4885ERCC4 4306/4885 |
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | ICMT 2292/4885ERCC1 3891/4885ERCC4 3567/4885 |
| US-10952435-B2 | Pyridine-2-carboxamides as nematocides | TUBA3C, CYCS, ACHE | ICMT 2471/4885ERCC1 4293/4885ERCC4 4306/4885 |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | ICMT 2292/4885ERCC1 3891/4885ERCC4 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.